- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Altimmune Inc (ALT)
The Altimmune share price today is 3.42, view NASDAQ ALT stock exchange data. Track the latest Altimmune share price with real-time updates on ALT stock performance including market cap, day range, 52-week range and dividend yield. Access ALT charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.25
3.43
52 wk Range
2.56
6.44
ALT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.253.43
52 wk Range
2.566.44
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
17.22
Upside
+403.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Form 8K Altimmune Inc For: 12 August- Investing.com
- Form 8K Altimmune Inc For: 12 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.22
(+403.57% Upside)
Altimmune Inc SWOT Analysis
Pemvidutide Promise | Explore pemvidutide's potential in MASH and obesity treatment, with unprecedented liver fat reduction and significant weight loss results |
Expanding Horizons | Delve into Altimmune's strategic expansion of pemvidutide applications to include alcohol use disorder and alcoholic liver disease |
Clinical Milestones | Anticipate key clinical trial outcomes, including the Phase 2b IMPACT trial for MASH, with top-line data expected in Q2 2025 |
Market Potential | Analyst price targets range from $12 to $28, with projected peak U.S. sales exceeding $2.5 billion for MASH indication alone |
Altimmune Inc Earnings Call Summary for Q2/2026
- Altimmune posted Q2 loss of $0.12/share, beating consensus of $0.15/share by 20%; shares rose 3.87% to $3.12, still 51.6% below 52-week high.
- Company holds $519M cash, raised $310M YTD including $225M April offering; runway extends through 2029 MASH trial readout per management.
- Phase II RECLAIM study in alcohol use disorder met primary endpoint; company planning FDA meeting to advance toward Phase III, seeking non-dilutive funding.
- Phase III PERFORMA MASH trial enrolling at 290-300 global sites targeting 18-24 month enrollment; Phase III ALD study RESTORE data expected H2 2027.
- R&D expenses rose 8.7% to $18.7M, G&A jumped 33.3% to $7.6M; net loss widened to $22.8M from $22.1M YoY despite narrower per-share loss.
Last Updated: 12-08-2026, 07:22 pm
Read Full TranscriptEarnings
Latest Release
12-08-2026
EPS / Forecast
-0.12 / -0.15
Revenue / Forecast
-- / 2K
Compare ALT to Peers and Sector
Metrics to compare | ALT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.2x | −2.3x | −0.4x | |
PEG Ratio | −0.19 | −0.06 | 0.00 | |
Price/Book | 1.4x | 2.4x | 2.6x | |
Price / LTM Sales | 21,459.7x | 36.5x | 3.0x | |
Upside (Analyst Target) | - | 274.1% | 48.7% | |
Fair Value Upside | Unlock | 13.8% | 7.0% | Unlock |
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Altimmune (ALT) Share Price Today?
The Altimmune share price today is 3.42.
What is the current Altimmune (ALT) share price and day range?
As of 05-09-2026, the Altimmune share price is 3.42, with a previous close of 3.23. The share price has ranged from 3.25 to 3.43 today, while the 52-week range spans from 2.56 to 6.44.
What Is the Altimmune Market Cap?
As of today, Altimmune market cap is 628.29M.
What Is the Altimmune (ALT) Share Price Target?
The average 12-month share price target for Altimmune is 17.22, with a high estimate of 28 and a low estimate of 11. 9 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +403.57% Upside potential.
What Is Altimmune's Earnings Per Share (TTM)?
The Altimmune EPS (TTM) is -0.73.
When Is the Next Altimmune Earnings Date?
Altimmune will release its next earnings report on 10-11-2026.
From a Technical Analysis Perspective, Is ALT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Altimmune Trade On?
Altimmune is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Altimmune?
The stock symbol for Altimmune is "ALT."
How Many Times Has Altimmune Stock Split?
Altimmune has split 2 times.
How Many Employees Does Altimmune Have?
Altimmune has 57 employees.
What Is the ALT Premarket Price?
ALT's last pre-market stock price is 3.26. The pre-market share volume is 35,080.00, and the stock has changed by 0.03, or 0.93%.
What Is the ALT After Hours Price?
ALT's last after hours stock price is 3.44, the stock has changed by 0.02, or 0.58%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.